"The final rule for 2025 poses several challenges to urology. Lobbying efforts to preserve telehealth access and the CF will continue, perhaps dragging into 2025," write Jonathan Rubenstein, MD, and ...

"I would say the fact that we performed 754 HoLEP procedures in 2024 is a reflection of the efficiency and the high quality of care that you receive at Northwestern," says Amy E. Krambeck, MD. In this ...

"As we all know, Medicare rules do not always follow CPT directives. The same is true in this case," write Jonathan Rubenstein, MD, and Mark Painter.

MPS2 test detects 94% of GG2 or higher prostate cancers using non-DRE urine samples, outperforming PSA and PCPTrc in accuracy. MPS2 models could reduce unnecessary biopsies by 36% to 42%, compared to ...

"If a practice has determined in writing that there are insurers whose policies advised that they will not accept this code, it seems reasonable not to report that code to that insurer even when ...

In this video, Bradley Roth, MS4, and Scott D. Lundy, MD, PhD, HCLD, outline the background and rationale for the study, “Routine Sperm Cryopreservation before Vasectomy Is Not Cost-Effective and Does ...

“The key here is I don’t believe that testosterone increases the risk of prostate cancer progression or biochemical recurrence," says Mohit Khera, MD, MBA, MPH. Overall, 39% of those who received a ...

"The three-year durability data from this study further validate the potential of JELMYTO in providing long-term disease control for patients with low-grade upper tract urothelial cancer,” says ...

Panelists discuss how BCG-unresponsive bladder cancer is defined by disease persistence/recurrence within 6 to 12 months of adequate BCG therapy. Treatment options ...

MiR-371a-3p demonstrates high sensitivity and specificity, outperforming traditional tumor markers in testicular cancer diagnosis and monitoring. MiR-371a-3p shows potential in early relapse detection ...

"The updated guideline includes numerous new, important recommendations that will enhance the ability of urologists to provide optimal, state-of-the-art care for infertile males,” says Robert E.

Panelists discuss how low-risk non–muscle-invasive bladder cancer (NMIBC) requires transurethral resection of bladder tumor (TURBT) with surveillance. Intermediate-risk disease needs adjuvant ...